I think you are wrong on two fronts.
Firstly, "that approval will likely require the adult trial" - that's not true. So you are wrong here!
Plan A is to discuss the new potency assay data with the FDA this month and that may be sufficient for the Ryoncil BLA Resubmission - i.e. possible approval of Ryoncil for Pediatric without being contingent on the adult trial.
If plan A is successful, then the adult trial has no impact on the approval of Ryoncil for Pediatric.
Secondly, if Plan A fails - then Plan B is activated.
With plan B, there is a need to get the adult trial started, yes started and not completed (as you constantly & wrongly repeat), to get an AA for Ryoncil for Pediatric.
This will require a surrogate end-point - what that is will need to be clarified by the FDA. This surrogate end-point does not need to wait for the adult trial to be completed. AA for Ryoncil for Pediatric will only be requested if and only if, plan A fails.
- Forums
- ASX - By Stock
- MSB
- Ann: FDA Supports Accelerated Approval Pathway for Heart Failure
Ann: FDA Supports Accelerated Approval Pathway for Heart Failure, page-355
-
- There are more pages in this discussion • 195 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B |
Open | High | Low | Value | Volume |
$1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 99680 | $1.15 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.16 | 31000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 99680 | 1.150 |
4 | 178484 | 1.145 |
3 | 40155 | 1.140 |
1 | 23155 | 1.135 |
3 | 88145 | 1.130 |
Price($) | Vol. | No. |
---|---|---|
1.155 | 31000 | 2 |
1.160 | 77919 | 3 |
1.165 | 2000 | 1 |
1.170 | 45455 | 3 |
1.175 | 49449 | 5 |
Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |